Phase III randomised trialPrevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer
Section snippets
Materials and methods
The study set-up has been described in detail previously [5]. In brief, the DAHANCA 6&7 multicentre trial randomised patients to receive either five or six weekly fractions of conventional radiotherapy. A total of 1485 patients with stage I–IV squamous cell carcinoma of the oral cavity, pharynx and larynx were randomised between January 1992 and December 1999, 1476 of these were eligible. DAHANCA 6 included 690 patients with tumours of the glottic larynx. DAHANCA 7 included 786 patients with
Results
Of the 1476 patients evaluable in the DAHANCA 6&7 trial 1229 (83%) were men and 247 (17%) were women. The medium age at randomisation was 62 years (range 20–88). The most frequent tumour localisation was glottic larynx (47%) followed by pharynx (29%). Tumour stages were 29%, 25%, 21% and 25% for stage I, II, III, IV, respectively. The distribution of patient and tumour characteristics was similar in the two groups at baseline and the adherence to radiotherapy was the same in the two groups, with
Discussion
The aim of this study was to analyse acute and late toxicity in the DAHANCA 6&7 study. The primary findings of the DAHANCA 6&7 study was that a moderate, one-week shortening of the overall treatment time applied to squamous cell carcinoma of the head and neck yielded better loco-regional control than conventional radiotherapy with same total dose and fraction size [5]. These findings have recently been confirmed in a similar trial sponsored by the International Atomic Energy Agency (IAEA) [6].
Conclusions
The moderate shortening of the overall treatment time with one week increased acute toxicity but all reactions were reversible. For all late endpoints except fibrosis and atrophy a decline in prevalence was observed in the years after radiotherapy, and there was no significant difference between randomisation arms in any of the late endpoints. Six fractions per week, resulting in a one-week reduction in overall treatment time relative to conventional radiotherapy represents a significant
Acknowledgments
Supported by the Danish Cancer Society, CIRRO – The Lundbeck Foundation Center for Interventional Research in Radiation Oncology, Dansk Kræftforskningsfond, and The Danish Council for Strategic Research.
References (35)
- et al.
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis
Lancet
(2006) - et al.
Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer?
Radiother Oncol
(1999) - et al.
Evidence-based review: quality of life following head and neck intensity-modulated radiotherapy
Radiother Oncol
(2010) - et al.
Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment ... now!
Int J Radiat Oncol Biol Phys
(1995) - et al.
Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial
Lancet
(2003) - et al.
Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial
Lancet Oncol
(2010) - et al.
Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial
Radiother Oncol
(1997) - et al.
Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial
Int J Radiat Oncol Biol Phys
(2006) - et al.
A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer
Radiother Oncol
(1997) - et al.
Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: results of a GORTEC randomized trial
Radiother Oncol
(2011)
Two-year results from a Swedish study on conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma - The ARTSCAN study
Radiother Oncol
Randomized clinical trial on continuous 7-days-a-week postoperative radiotherapy for high-risk squamous cell head-and-neck cancer: a report on acute normal tissue reactions
Radiother Oncol
A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003
Int J Radiat Oncol Biol Phys
A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer
Radiother Oncol
Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial
Radiother Oncol
Normal tissue effects: reporting and analysis
Semin Radiat Oncol
The recording of morbidity related to radiotherapy
Radiother Oncol
Cited by (0)
- 1
On behalf of the DAHANCA group.